Ajanta Pharma , a specialty pharmaceutical formulation company, has announced Monday, November 10, 2025, as the record date for its first interim dividend payment. The company made this disclosure to the BSE and NSE stock exchanges, demonstrating its commitment to shareholder value.

Dividend Details

The Board of Directors of Ajanta Pharma have approved a first interim dividend for the financial year 2026. Key details of the dividend are as follows:

Financial Performance

The dividend announcement comes on the heels of Ajanta Pharma's financial performance for the second quarter and first half of FY 2026:

• Q2 FY 2026 revenue from operations increased by 14% to Rs. 1,354.00 crore
• Q2 FY 2026 profit after tax (PAT) grew by 20% to Rs. 260.00 crore
• H1 FY 2026 revenue from operations rose by 14% to Rs. 2,656.00 crore
• H1 FY 2026 PAT increased by 12% to Rs. 516.00 crore

Segment Performance

Ajanta Pharma's growth was driven by performances across its business segments:

Market Position

According to IQVIA MAT September 2025 data, Ajanta Pharma's India branded generics performance exceeded the Indian Pharmaceutical Market (IPM) growth by 32%. The company showed growth in key therapeutic areas:

Investor Information

Investors and shareholders should take note of the November 10, 2025 record date to be eligible for the interim dividend payment.

This dividend announcement, coupled with the company's financial performance, underscores Ajanta Pharma's commitment to delivering value to its shareholders while maintaining growth across its business segments.

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, has announced robust financial results for the second quarter of fiscal year 2026, demonstrating strong growth across key metrics.

Financial Highlights

The company reported impressive year-over-year growth in its Q2 FY 2026 performance:

The company experienced a mark-to-market forex loss of Rs. 41.00 cr. Excluding this impact, the adjusted EBITDA stood at Rs. 369.00 cr., reflecting a 9.00% growth with an EBITDA margin of 27.00%. Similarly, the adjusted PAT grew by 23.00%, with a margin of 22.00%.

Segment-wise Performance

Ajanta Pharma's business segments showed varied performance:

The company's branded generics business, which accounts for 72.00% of total revenue, grew by 8.00% overall. The US generics segment showed remarkable growth of 48.00%, while the Africa Institution business experienced a decline.

Market Performance

According to IQVIA MAT September 2025 data, Ajanta Pharma's India branded generic performance exceeded the Indian Pharmaceutical Market (IPM) growth by 32.00%. This growth was primarily driven by:

• Volume increase: Exceeded IPM by 115.00%
• New launches: Exceeded IPM by 39.00%

The company outperformed the IPM in key therapeutic areas:

R&D and Product Pipeline

Ajanta Pharma maintains a strong focus on research and development:

• R&D expenses for Q2 FY 2026: Rs. 63.00 cr. (5.00% of revenue)
• R&D expenses for H1 FY 2026: Rs. 119.00 cr. (5.00% of revenue)

The company's ANDA (Abbreviated New Drug Application) status as of H1 FY 2026:

• Total ANDAs commercialized: 50
• Awaiting approval with US FDA: 22
• Tentative approvals: 2

Dividend Announcement

The Board of Directors has approved a first interim dividend of Rs. 28.00 per share for the face value of Rs. 2.00 per share, amounting to Rs. 350.00 cr.

Future Outlook

Ajanta Pharma continues to focus on strategic priorities, including:

1. New product launches across markets
2. Gaining market share in existing products
3. Enhancing field force productivity
4. Expanding into new countries and therapies
5. Optimizing expenses through cost management and digitalization

With a strong product portfolio under development and registration, Ajanta Pharma is well-positioned for continued growth in the pharmaceutical market.

The company's performance demonstrates its resilience and ability to navigate challenging market conditions while maintaining a focus on growth and shareholder value.